1,241
Participants
Start Date
October 16, 2017
Primary Completion Date
December 22, 2017
Study Completion Date
December 22, 2017
Micronized progesterone
Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
Micronized progesterone
Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
Dydrogesterone
Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
City Clinical Hospital №68, Moscow
Pirogov Russian National Research Medical University (RNRMU), Moscow
Maternity hospital №17, Moscow
Central district hospital, Zhukovsky
Chekhov district hospital №1, Chekhov
Regional Perinatal Center, Yaroslavl
Regional perinatal center, Kursk
City Clinical Hospital № 8, Voronezh
City Clinical Hospital №16, Kazan'
Сity hospital №7, Samara
Stavropol Central District Hospital, Stavropol
City Clinical Hospital of the Demsk District, Ufa
Сentral city hospital, Kamensk-Uralsky
Center for Family Planning and Reproduction, Novosibirsk
Maternity hospital №2, Omsk
Maternity hospital №6, Omsk
Maternity hospital №1, Krasnoyarsk
Lead Sponsor
Collaborators (1)
Clinical Research Laboratory, CRO, Russia
UNKNOWN
Besins Healthcare
INDUSTRY